
Context Therapeutics and Integral Molecular have announced a research collaboration and licensing agreement for the development of an anti-claudin 6 …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

